The antioxidant effect of ubiquinone and combined therapy on mitochondrial function in blood cells in non-proliferative diabetic retinopathy: A randomized, double-blind, phase IIa, placebo-controlled study. (3rd July 2016)

• Record Type: Journal Article
• Authors: Rodríguez-Carrizalez, Adolfo Daniel; Castellanos-González, José Alberto; Martínez-Romero, Esaú César; Miller-Arrevillaga, Guillermo; Román-Pintos, Luis Miguel; Pacheco-Moisés, Fermín Paul; Miranda-Díaz, Alejandra Guillermina
• Is Part Of: Redox report. Volume 21:Number 4(2016)
• Page Start: 190
• Page End: 195
• Publication Date: 2016-07-03
• Subjects: Diabetes mellitus -- Diabetic retinopathy -- Antioxidants -- Oxidative stress -- Co-enzime Q10 -- Mitochondrial function; Free radicals (Chemistry) -- Pathophysiology -- Periodicals; Oxidation, Physiological -- Periodicals; 541.224
• DOI: 10.1179/1351000215Y.0000000032
• Languages: English
• ISSNs: 1351-0002

Abstract

Abstract : Objectives : To evaluate the effect of ubiquinone and combined antioxidant therapy on mitochondrial function in non-proliferative diabetic retinopathy (NPDR) in a randomized, double-blind, phase IIa, placebo-controlled, clinical trial. Three groups of 20 patients were formed: Group 1, ubiquinone; Group 2, combined therapy; and Group 3, placebo (one daily dose for 6 months). Methods : Fluidity of the submitochondrial membrane in platelets was determined by examining intensity of fluorescence between the monomer ( I m ) and excimer ( I e ). Hydrolytic activity of the mitochondrial F0 F1 -ATPase was evaluated with the spectrophotometric method. Results : Normal, baseline submitochondrial membrane fluidity, 0.24 ± 0.01 I e / I m, was significantly diminished in the three study groups vs. normal values ( P < 0.0001); placebo, 0.14 ± 0.01 I e / I m ; ubiquinone, 0.14 ± 0.01 I e / I m ; and combined therapy, 0.13 ± 0.00 I e / I m . Afterward, it increased significantly ( P < 0.0001), the ubiquinone group 0.22 ± 0.01 I e / I m, combined therapy group, 0.19 ± 0.01 I e / I m ; with no changes the placebo group. Baseline hydrolytic activity of the F0 F1 -ATPase enzyme increased in the three study groups vs. normal values (184.50 ± 7.84 nmol PO4 ), placebo, 304.12 ± 22.83 nmol PO4 ( P < 0.002); ubiquinone, 312.41 ± 25.63 nmol PO4 ( P < 0.009); and combined therapy, 371.28 ± 33.50 nmol PO4 ( P < 0.002). Afterward, a significant decrease the enzymatic activity: ubiquinone, 213.25 ± 14.19 nmol PO4 ( P < 0.001); and combined therapy, 225.55 ± 14.48 nmol PO4 ( P < 0.0001). Discussion : Mitochondrial dysfunction significantly improved in groups of NPDR patients treated with antioxidants.